443 related articles for article (PubMed ID: 31427301)
1. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301
[TBL] [Abstract][Full Text] [Related]
2. Clinically Relevant Epithelial Lining Fluid Concentrations of Meropenem with Ciprofloxacin Provide Synergistic Killing and Resistance Suppression of Hypermutable Pseudomonas aeruginosa in a Dynamic Biofilm Model.
Bilal H; Bergen PJ; Tait JR; Wallis SC; Peleg AY; Roberts JA; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366710
[TBL] [Abstract][Full Text] [Related]
3. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
[TBL] [Abstract][Full Text] [Related]
4. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
Landersdorfer CB; Rees VE; Yadav R; Rogers KE; Kim TH; Bergen PJ; Cheah SE; Boyce JD; Peleg AY; Oliver A; Shin BS; Nation RL; Bulitta JB
Antimicrob Agents Chemother; 2018 Apr; 62(4):. PubMed ID: 29437610
[TBL] [Abstract][Full Text] [Related]
5. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
Rees VE; Yadav R; Rogers KE; Bulitta JB; Wirth V; Oliver A; Boyce JD; Peleg AY; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
[TBL] [Abstract][Full Text] [Related]
6. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
Yadav R; Bergen PJ; Rogers KE; Kirkpatrick CMJ; Wallis SC; Huang Y; Bulitta JB; Paterson DL; Lipman J; Nation RL; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636062
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
Breen SKJ; Harper M; López-Causapé C; Rogers KE; Tait JR; Smallman TR; Lang Y; Lee WL; Zhou J; Zhang Y; Bulitta JB; Nation RL; Oliver A; Boyce JD; Landersdorfer CB
Int J Antimicrob Agents; 2024 Jun; 63(6):107161. PubMed ID: 38561094
[TBL] [Abstract][Full Text] [Related]
8. Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
Agyeman AA; López-Causapé C; Rogers KE; Lucas DD; Cortés-Lara S; Gomis-Font MA; Fraile-Ribot P; Figuerola J; Lang Y; Franklyn ERT; Lee WL; Zhou J; Zhang Y; Bulitta JB; Boyce JD; Nation RL; Oliver A; Landersdorfer CB
Int J Antimicrob Agents; 2023 Sep; 62(3):106887. PubMed ID: 37315906
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.
Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O
Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
Yadav R; Bulitta JB; Wang J; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of ceftazidime plus tobramycin combination dosage regimens against hypermutable Pseudomonas aeruginosa isolates at simulated epithelial lining fluid concentrations in a dynamic in vitro infection model.
Tait JR; Bilal H; Kim TH; Oh A; Peleg AY; Boyce JD; Oliver A; Bergen PJ; Nation RL; Landersdorfer CB
J Glob Antimicrob Resist; 2021 Sep; 26():55-63. PubMed ID: 34023531
[TBL] [Abstract][Full Text] [Related]
12. Impact of meropenem in combination with tobramycin in a murine model of Pseudomonas aeruginosa pneumonia.
Louie A; Liu W; Fikes S; Brown D; Drusano GL
Antimicrob Agents Chemother; 2013 Jun; 57(6):2788-92. PubMed ID: 23571540
[TBL] [Abstract][Full Text] [Related]
13. Spatiotemporal pharmacodynamics of meropenem- and tobramycin-treated Pseudomonas aeruginosa biofilms.
Haagensen J; Verotta D; Huang L; Engel J; Spormann AM; Yang K
J Antimicrob Chemother; 2017 Dec; 72(12):3357-3365. PubMed ID: 28961810
[TBL] [Abstract][Full Text] [Related]
14. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
Yadav R; Bulitta JB; Nation RL; Landersdorfer CB
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
[TBL] [Abstract][Full Text] [Related]
15. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
[No Abstract] [Full Text] [Related]
16. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
17. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
Yadav R; Rogers KE; Bergen PJ; Bulitta JB; Kirkpatrick CMJ; Wallis SC; Paterson DL; Nation RL; Lipman J; Roberts JA; Landersdorfer CB
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463528
[TBL] [Abstract][Full Text] [Related]
18. Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.
Rees VE; Bulitta JB; Oliver A; Tsuji BT; Rayner CR; Nation RL; Landersdorfer CB
J Antimicrob Chemother; 2016 Nov; 71(11):3157-3167. PubMed ID: 27521357
[TBL] [Abstract][Full Text] [Related]
19. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model.
Lora-Tamayo J; Murillo O; Bergen PJ; Nation RL; Poudyal A; Luo X; Yu HY; Ariza J; Li J
J Antimicrob Chemother; 2014 Sep; 69(9):2434-42. PubMed ID: 24833752
[TBL] [Abstract][Full Text] [Related]
20. Breaking the Vicious Cycle of Antibiotic Killing and Regrowth of Biofilm-Residing
Müsken M; Pawar V; Schwebs T; Bähre H; Felgner S; Weiss S; Häussler S
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30297365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
